Ligand Pharmaceuticals Inc. filings document the regulatory record for a Nasdaq-listed biopharmaceutical royalty aggregator with common stock trading under LGND. The company’s disclosures cover royalty portfolio economics, technology licenses, partner-product clinical and regulatory matters, operating results, milestone payments, commercial royalties, Captisol® material sales, and NITRICIL™ licensing.
Ligand’s SEC record also includes Form 8-K reports on material agreements, license-program rights, credit-agreement amendments, Regulation FD communications, capital-structure disclosures, and financial results. Proxy materials describe board matters, shareholder voting items, executive compensation, equity awards, and governance practices for the public company.
Form 4 Filing Details: Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals (LGND), reported a sale of 500 shares of common stock on June 23, 2025, at an average price of $114.0843 per share.
Following the transaction, Reardon continues to hold 31,903 shares directly. The sale represents approximately 1.5% of his direct holdings. The transaction was reported within the required two-business-day filing deadline, with the Form 4 being filed on June 24, 2025.
This insider sale occurs at a time when LGND executives must comply with SEC regulations regarding insider trading. The filing indicates this was a direct ownership transaction, and no derivative securities were involved in this report.